50 Scientists Just Issued a Five-Step Plan to Stop the Antifungal Resistance Crisis

50 Scientists Just Issued a Five-Step Plan to Stop the Antifungal Resistance Crisis

The WHO's Global Action Plan on Antimicrobial Resistance has existed since 2015. It was built primarily around bacterial and viral pathogens. Fungi, despite representing a growing and increasingly drug-resistant threat to human health, received minimal attention. That is the gap a coalition of fifty researchers from sixteen institutions around the world is now working to close, and they've done it by publishing a detailed five-step plan in Nature Medicine that is timed to influence the WHO's 2026 update to that very document.

The research was led by Professor Paul Verweij, medical microbiologist at Radboud University Medical Centre in the Netherlands. The paper, titled "Closing the Gap on Antifungal Resistance," is the most coordinated international call to action on fungal drug resistance the scientific community has produced.

Why Fungi Have Been Left Out of the AMR Conversation

Antimicrobial resistance is not a new topic. The risks of overusing antibiotics, the emergence of resistant bacterial strains, and the inadequacy of the drug development pipeline have all been extensively covered for years. What has received far less attention is that the same dynamics apply to antifungal drugs, and the consequences are just as serious for vulnerable patients.

Environmental fungi are developing resistance to antifungal drugs at an increasing rate. For most healthy people this creates no immediate health risk, but for patients with weakened immune systems the situation is more serious. Resistant fungi can cause severe infections that are substantially harder to treat than those caused by susceptible strains, and the treatment options available when first-line drugs fail are limited.

The organisms raising the most clinical concern span a range of severity. Skin fungi typically cause manageable conditions like athlete's foot or nail infections, but a growing number of resistant species are producing infections that are difficult to treat and slow to resolve. Trichophyton indotineae, a drug-resistant skin pathogen spreading through several continents, is one of the more visible recent examples. At the more serious end of the spectrum, Candida auris and Aspergillus fumigatus represent threats in a different category entirely.

Aspergillus fumigatus is a mould that most people inhale without consequence. In patients with compromised immunity it can cause serious lung damage, and Verweij's team notes it has become a more frequent presence in ICUs, particularly among patients with severe influenza. Candida auris, which ShroomSpy has covered separately in the context of its rapid rise in Texas, carries a mortality rate of around one in three for invasive infections.

The Agricultural Connection Nobody Is Fixing

One of the most important findings in the Nature Medicine paper is the mechanism driving resistance growth in the community rather than in hospitals. The source, it turns out, is agriculture, and the pathway from field to ICU is more direct than most people realize.

Fungal resistance is not primarily a hospital-acquired phenomenon. It originates in the environment. The fungicides used in agriculture to protect crops against plant diseases are chemically similar to the antifungal drugs used in clinical medicine, because both target the same biological mechanisms in fungal cells. Prolonged exposure to agricultural fungicides selects for resistant strains in environmental fungal populations. Those resistant strains then spread through the air, reaching communities and eventually healthcare settings where they can infect vulnerable patients. The resistance that develops on a farm can directly reduce the effectiveness of treatments available in an ICU.

Professor Michaela Lackner of the Medical University of Innsbruck described the dual use of antifungal targets across medicine and agriculture as a key driver accelerating resistance, with effects running directly from fields into clinical settings. Aligning agricultural chemical authorizations with human health risk assessments is, in her framing, a practical necessity rather than a secondary policy concern.

This is the core of what researchers call a "One Health" approach: recognizing that human health, animal health, and environmental health are not separate systems. Resistance that develops in a Dutch tulip field can end up in an ICU in Texas. Managing it requires coordinated oversight across sectors that have historically operated independently.

The Five-Step Plan

The Nature Medicine paper presents a structured five-step framework that the research coalition is urging WHO member states to adopt as part of the 2026 Global Action Plan update. The steps are awareness, surveillance, infection prevention and control, optimized use, and investment.

Each step addresses a specific gap in the current response.

Awareness targets the fact that antifungal resistance remains poorly understood by the public, by policymakers, and by many clinicians who do not routinely encounter severe fungal infections. Raising the profile of the issue is a precondition for everything else on the list.

Surveillance addresses the near-total absence of systematic global monitoring for antifungal resistance. Without consistent, comparable data across countries and clinical settings, it is impossible to track how resistance is spreading, which species are most affected, or whether interventions are working. This gap is particularly acute in lower-income countries where diagnostic capacity is limited.

Infection prevention and control focuses on healthcare settings, where resistant fungi like Candida auris spread between patients through contaminated surfaces and inadequate containment protocols. Tightening those protocols and ensuring they are consistently applied is one of the most immediate levers available.

Optimized use covers stewardship: using antifungal drugs more selectively in both clinical and agricultural settings to reduce the selection pressure that drives resistance development.

Investment is the foundational step that makes the others viable. New antifungal drug development is severely underfunded. Only five new classes of antifungal drugs have been developed across the past 75 years, a direct consequence of the same poor commercial economics that have suppressed antibiotic development. Investment in affordable diagnostics, which currently do not exist at adequate scale in many healthcare systems, is equally urgent.

The WHO Window and Why Timing Matters

The 2026 update to the WHO's Global Action Plan on Antimicrobial Resistance represents a specific, time-bound opportunity. Global health policy documents of this kind set the agenda for national governments, funding bodies, and research institutions for years after their publication. Getting antifungal resistance included with concrete milestones and dedicated funding in the 2026 update would be meaningfully different from another iteration that treats fungi as a footnote to the bacterial resistance story.

Verweij's position, shared across the fifty co-authors of the paper, is that failing to act now risks repeating the same policy mistakes that allowed bacterial antibiotic resistance to reach crisis proportions before serious coordinated action began. The warning from antibacterial resistance is that delay compounds the problem. Fungi that are mildly resistant today become harder to treat as selection pressure accumulates and the strains that survive antifungal exposure become dominant in the population.

Haileyesus Getahun, director of the WHO program for global coordination on antimicrobial resistance, has acknowledged the evidence gap directly, noting that better data on fungal infections and resistance patterns are needed to improve the global response to priority fungal pathogens. The five-step plan is designed to generate that data while simultaneously pushing for the policy environment that would allow it to be acted upon.

Where This Fits in the Bigger Picture

What the Radboudumc-led Nature Medicine paper adds is the structural layer: a coordinated scientific consensus on what policy needs to look like, timed to land at the moment the WHO is revising the global framework that governs how countries respond to antimicrobial threats.

The science is generating real leads. The policy infrastructure that would allow those leads to translate into treatments and prevention strategies is still being built. The five-step plan is an attempt to accelerate that construction before the resistance curve runs further ahead of the response.

Ready to take your mycology journey to the next level? Browse our full range of mushroom products and find everything you need to grow, forage, and thrive.